Focus: Alkeus Pharmaceuticals is a small-stage ophthalmology-focused company based in Cambridge, MA with 1-50 employees developing treatments for retinal diseases. The company is advancing a Phase 3 program in Stargardt Disease, a rare inherited retinal dystrophy.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
2 added, 1 removed. Backfill posture.
Best suited for early-career or mission-driven professionals seeking outsized impact in rare disease ophthalmology, but requires comfort with financial ambiguity and bootstrapped-stage risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Alkeus Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Alkeus Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
+2 more
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles